Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

UCB To SHAPE Up With Cost-Cutting Plan, Two Years After Schwarz Buy

Executive Summary

UCB is joining the ranks of pharma companies embarking on major cost cutting programs, as the Belgian company decides to focus on specialty markets two years after bulking up via the acquisition of Schwarz Pharma

You may also be interested in...



UCB’s Neupro Manufacturing Problems Hold Up Approval For Advanced Parkinson’s Disease

UCB must resolve the issue of drug crystal formation in the Neupro patch before it can be approved for two supplemental indications.

UCB’s Neupro Manufacturing Problems Hold Up Approval For Advanced Parkinson’s Disease

UCB must resolve the issue of drug crystal formation in the Neupro patch before it can be approved for two supplemental indications.

UCB’s Vimpat Falters In Diabetic Pain

Neuropathy filing is "not approvable" at FDA, but seizure indication is on track, firm says.

Related Content

UsernamePublicRestriction

Register

PS050082

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel